Effects of adding intravenous nicorandil to standard therapy on cardiac sympathetic nerve activity and myocyte dysfunction in patients with acute decompensated heart failure.

Abstract

PURPOSE:

Nicorandil, an adenosine triphosphate-sensitive potassium channel opener, improves cardiac sympathetic nerve activity (CSNA) in ischemic heart disease or chronic heart failure. However, its effects on CSNA and myocyte dysfunction in acute heart failure (AHF) remain unclear. We investigated the effects of adding intravenous nicorandil to standard therapy on CSNA and myocyte dysfunction in AHF.

METHODS:

We selected 70 patients with mild to moderate nonischemic AHF who were treated with standard conventional therapy soon after admission. Thirty-five patients were assigned to additionally receive intravenous nicorandil (4-12 mg/h; group A), whereas the remaining patients continued their current drug regimen (group B). Delayed total defect score (TDS), delayed heart to mediastinum count (H/M) ratio, and washout rate (WR) were determined by (123)I-metaiodobenzylguanidine (MIBG) scintigraphy within 3 days of admission and 4 weeks later. High sensitivity troponin T (hs-TnT) level was also measured at the same time points.

RESULTS:

After treatment, MIBG scintigraphic parameters significantly improved in both groups. However, the extent of the changes in these parameters in group A significantly exceeded the extent of the changes in group B [TDS -11.3 ± 4.3 in group A vs -4.0 ± 6.0 in group B (p < 0.01); H/M ratio 0.31 ± 0.16 vs 0.14 ± 0.16 (p < 0.01); WR -13.8 ± 7.8 % vs -6.1 ± 8.9 % (p < 0.01)]. The hs-TnT level decreased significantly from 0.052 ± 0.043 to 0.041 ± 0.033 ng/ml (p < 0.05) in group A, but showed no significant change in group B. Moreover, in both groups, no relationships between the extent of changes in MIBG parameters and hs-TnT level were observed.

CONCLUSION:

Adding intravenous nicorandil to standard therapy provides additional benefits for CSNA and myocyte dysfunction over conventional therapy alone in AHF patients. Furthermore, the mechanisms of improvement in CSNA and myocyte dysfunction after nicorandil treatment in AHF patients were distinct.

• Authors: Shu Kasama, Takuji Toyama, Ryuichi Funada, Noriaki Takama, Norimichi Koitabashi, Shuichi Ichikawa, Yasuyuki Suzuki, Naoya Matsumoto, Yuichi Sato, Masahiko Kurabayashi
• Journal: European journal of nuclear medicine and molecular imaging (Eur J Nucl Med Mol Imaging) Vol. 42 Issue 5 Pg. 761-70 (Apr 2015) ISSN: 1619-7089 [Electronic] Germany
• PMID: 25634117 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Arrhythmia Agents
• Nicorandil

Topics

• Administration, Intravenous
• Aged
• Aged, 80 and over
• Anti-Arrhythmia Agents (administration & dosage, pharmacology, therapeutic use)
• Female
• Heart (drug effects, innervation)
• Heart Failure (diagnostic imaging, drug therapy)
• Humans
• Male
• Middle Aged
• Myocytes, Cardiac (drug effects)
• Nicorandil (administration & dosage, pharmacology, therapeutic use)
• Radionuclide Imaging
• Sympathetic Nervous System (drug effects)